Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6609 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-09-24 (malaysiasun.com)
Holtec CEO lauds PM Modi's vision to support India's clean energy goals
Prime Minister Narendra Modi roundtable meeting with CEOs of global technology and energy companies in New York has sparked significant discussions on India
Read more
2023-07-07 (reuters.com)
US FDA grants standard approval of Eisai/Biogen Alzheimer's drug
A new milestone for a fatal disease that has eluded drugmakers' efforts for decades.
Read more
2021-06-22 (bostonglobe.com)
New drug could cost government as much as it spends on NASA
“It’s unfathomable,” said Tricia Neuman, executive director of the Kaiser Family Foundation’s program on Medicare policy. “These are crazy numbers.”
Read more
(nationalezorggids.nl)
Bruins is negotiating a reimbursement arrangement for MS drug Fampyra
In recent weeks, Minister Bruins of Medical Care has had a number of discussions with Biogen, the manufacturer of the MS drug Fampyra. The outcome is that Biogen sets up a reimbursement scheme in which patients can - retroactively - immediately receive a significant part of the purchase costs of the medicine Fampyra back from Biogen through a declaration. Bruins informed the House of Representatives of this yesterday, the government reports.
Read more